WEBULL
News
BCTXW
0.0080
-10.11%
-0.0009
Weekly Report: what happened at BCTXW last week (0202-0206)?
Weekly Report · 22h ago
Weekly Report: what happened at BCTXW last week (0126-0130)?
Weekly Report · 02/02 09:00
BriaCell Therapeutics Reports Tumor Regression in Phase 2 Study of Bria-IMT for Metastatic Breast Cancer
Reuters · 01/28 12:30
BRIACELL PATIENTS’ IMAGES SHOW REGRESSION AND RESOLUTION OF METASTASIZED TUMORS AND IMMUNE ACTIVATION
Reuters · 01/28 12:30
BriaCell Reports Extended Survival in Phase 2 Metastatic Breast Cancer Trial
Reuters · 01/27 17:05
BriaCell Highlights Extended >18-47 MONTHS SURVIVAL IN PHASE 2 METASTATIC BREAST CANCER PATIENTS
Reuters · 01/27 12:30
BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients
Barchart · 01/27 06:30
Weekly Report: what happened at BCTXW last week (0119-0123)?
Weekly Report · 01/26 09:00
Weekly Report: what happened at BCTXW last week (0112-0116)?
Weekly Report · 01/19 09:00
BRIACELL THERAPEUTICS ANNOUNCES CLOSING OF US$30 MILLION PUBLIC OFFERING
Reuters · 01/15 21:05
US-LISTED SHARES OF BRIACELL THERAPEUTICS TUMBLE 55% AFTER CO PRICES $30 MLN PUBLIC OFFERING
Reuters · 01/14 14:31
BRIACELL THERAPEUTICS CORP - UNITS SOLD AT $5.59 PER UNIT FOR $30 MLN GROSS PROCEEDS
Reuters · 01/14 02:00
BriaCell Therapeutics Announces Pricing of $30 million Public Offering
Barchart · 01/13 20:00
BriaCell Reports 11-Month Complete Lung Metastasis Resolution in Metastatic Breast Cancer Trial
Reuters · 01/13 12:30
Weekly Report: what happened at BCTXW last week (0105-0109)?
Weekly Report · 01/12 09:00
BriaCell Therapeutics Reports Positive Phase 3 Data for Bria-IMT Regimen in Metastatic Breast Cancer
Reuters · 01/07 15:35
Weekly Report: what happened at BCTXW last week (1229-0102)?
Weekly Report · 01/05 09:00
Weekly Report: what happened at BCTXW last week (1222-1226)?
Weekly Report · 12/29/2025 09:00
Weekly Report: what happened at BCTXW last week (1215-1219)?
Weekly Report · 12/22/2025 09:00
“ELEVEN CLINICAL TRIALS THAT WILL SHAPE MEDICINE IN 2026” – BRIACELL PHASE 3 TRIAL FEATURED IN NATURE MEDICINE
Reuters · 12/18/2025 12:30
More
Webull provides a variety of real-time BCTXW stock news. You can receive the latest news about Briacell Therapeutics Corp through multiple platforms. This information may help you make smarter investment decisions.
About BCTXW
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops immunotherapies to transform cancer care. The Company’s lead drug candidate, Bria-IMT, is a cell-based patented immunotherapy that stimulates a patient’s own cancer fighting cells to attack and destroy breast cancer tumors. The Company is advancing its targeted immunotherapy program by prioritizing a Phase II clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor. The Company is focused on conducting a Phase I/IIa clinical trial of Bria-IMT in a combination study with Incyte’s immune PD-1 inhibitor, retifanlimab, in advanced breast cancer. The Company is also developing Bria-OTS, an off-the-shelf personalized approach to whole cell cancer immunotherapy. The Bria-OTS immunotherapy is based on a patient’s HLA-type. Its pipeline also includes Bria-Pros, Bria-Lung, Bria-Mel and sCD80, which are in development to treat various cancers.